Trinity biotech enters oncology space with acquisition of prostate cancer focused epicapture

Dublin, oct. 25, 2024 (globe newswire) -- trinity biotech plc (nasdaq: trib), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquisition of epicapture limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer. this acquisition marks trinity biotech's strategic expansion into the oncology diagnostics market.
TRIB Ratings Summary
TRIB Quant Ranking